Xilio Therapeutics's three largest insider shareholders as of March 23, 2026 are Impact Medicine Fund Lp Sv7 (TenPercentOwner, 3.23Mn shares), Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 2.81Mn shares), Venture Fund Xi, L.P. Atlas (TenPercentOwner, 2.75Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sciences, Inc. Gilead | 9,105,451 | 0 | 19 Dec, 2024 | |
| Impact Medicine Fund Lp Sv7 | 1,613,632 | 1,613,632 | 03 Nov, 2021 | |
| Capital Life Sciences Investors, Llc Bain | 0 | 2,805,413 | 10 Dec, 2021 | |
| Venture Fund Xi, L.P. Atlas | 2,019,563 | 734,546 | 09 Feb, 2024 | |
| Venture Fund Iv, L.P. Rivervest | 0 | 1,441,444 | 26 Oct, 2021 | |
| Springs Capital Management Lp Rock | 0 | 1,256,472 | 26 Oct, 2021 | |
| Kgaa Merck | 0 | 680,825 | 26 Oct, 2021 | |
| Rene Russo | President And Ceo | 325,422 | 0 | 05 Jan, 2026 |
| Venture Investments, Llc Alexandria | 166,423 | 0 | 26 Oct, 2021 | |
| Katarina Luptakova | Chief Medical Officer | 33,250 | 0 | 05 Jan, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 0 | 05 Jan, 2026 |
| Kevin M. Brennan | Svp, Finance And Accounting | 6,371 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Feb, 2026 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 3,739,000 | $0.53 | 40,384,266 | D | P |
| 01 Jan, 2026 | Christopher James Frankenfield | Common Stock | A | 19,375 | - | 31,796 | D | M |
| 01 Jan, 2026 | Rene Russo | Common Stock | A | 44,250 | - | 325,422 | D | M |
| 01 Jan, 2026 | Katarina Luptakova | Common Stock | A | 16,625 | - | 33,250 | D | M |
| 01 Jan, 2026 | Kevin M. Brennan | Common Stock | A | 5,000 | - | 8,197 | D | M |
| 02 Jan, 2026 | Kevin M. Brennan | Common Stock | D | 1,826 | $0.64 | 6,371 | D | S |
| 31 Dec, 2025 | Rene Russo | Stock Option (right to buy) | A | 1,500,258 | $0.00 | 1,500,258 | D | A |
| 02 Jan, 2026 | Christopher James Frankenfield | Common Stock | D | 7,030 | $0.64 | 24,766 | D | S |
| 31 Dec, 2025 | Katarina Luptakova | Stock Option (right to buy) | A | 451,885 | $0.00 | 451,885 | D | A |
| 31 Dec, 2025 | Kevin M. Brennan | Stock Option (right to buy) | A | 95,221 | $0.00 | 95,221 | D | A |
| 01 Jan, 2026 | Katarina Luptakova | Restricted Stock Units | D | 16,625 | $0.00 | 33,250 | D | M |
| 01 Jan, 2026 | Rene Russo | Restricted Stock Units | D | 44,250 | $0.00 | 88,500 | D | M |
| 31 Dec, 2025 | Christopher James Frankenfield | Stock Option (right to buy) | A | 668,789 | $0.00 | 668,789 | D | A |
| 01 Jan, 2026 | Kevin M. Brennan | Restricted Stock Units | D | 5,000 | $0.00 | 10,000 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Restricted Stock Units | D | 19,375 | $0.00 | 38,750 | D | M |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 13,335,000 | $0.75 | 36,645,266 | D | X |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Series B Warrants (right to buy) | D | 13,335,000 | $0.00 | 0 | D | X |
| 21 Nov, 2025 | Katarina Luptakova | Stock Option (right to buy) | A | 625,000 | $0.00 | 625,000 | D | A |
| 21 Nov, 2025 | Rene Russo | Stock Option (right to buy) | A | 2,075,000 | $0.00 | 2,075,000 | D | A |
| 21 Nov, 2025 | Kevin M. Brennan | Stock Option (right to buy) | A | 131,700 | $0.00 | 131,700 | D | A |